Austedo (deutetrabenazine) can start reducing involuntary movements within the first two weeks, though most people need several weeks of gradual dose increases before reaching their best response. In clinical trials, measurable improvement appeared as early as week two at higher doses, with more consistent results by week four. The full process of finding your optimal dose typically takes about eight weeks.
What Happens in the First Few Weeks
Austedo isn’t a medication you start at full strength. The dose is increased slowly, week by week, which means the timeline for feeling results is closely tied to the titration schedule. For tardive dyskinesia, the starting dose is 12 mg per day (split into two doses). For Huntington’s chorea, it’s 6 mg once daily. From there, your doctor increases the dose by 6 mg per week until your involuntary movements improve or side effects limit further increases.
In the AIM-TD clinical trial for tardive dyskinesia, patients on the two higher doses (24 mg and 36 mg per day) showed statistically significant improvement by week two. A separate trial, ARM-TD, found a clear treatment benefit by week four, with involuntary movement scores dropping meaningfully compared to placebo. So while some people notice changes early, a realistic expectation is that noticeable improvement builds over the first month or so as the dose climbs toward its therapeutic range.
The maximum daily dose is 48 mg for most patients. Since dose increases happen weekly, reaching that ceiling could take roughly seven to eight weeks from the start. Clinical trials used an eight-week titration period followed by four weeks of maintenance at the final dose, and outcomes were measured at the 12-week mark. That gives a reasonable window: you should have a good sense of whether the medication is working within about three months.
Why the Ramp-Up Takes So Long
Austedo works by limiting a transport protein that packages certain brain chemicals (dopamine, serotonin, and norepinephrine) into storage compartments in nerve cells. With less of these chemicals available for release, the misfiring signals that cause involuntary movements quiet down. The medication itself reaches effective blood levels relatively quickly, but the slow titration exists for safety, not pharmacology. Increasing the dose too fast raises the risk of side effects like drowsiness, restlessness, or a worsening of mood.
The drug’s chemical design actually helps with consistency. Austedo is a modified version of an older medication (tetrabenazine) with hydrogen atoms swapped for a heavier form called deuterium. This small change makes the drug break down more slowly in the body, resulting in a longer half-life and more stable blood levels throughout the day. That’s why Austedo can be taken twice daily instead of the three times a day required by its predecessor, and why its effects tend to be smoother and more predictable.
How Austedo Compares to Ingrezza
Ingrezza (valbenazine) is the other major medication in this class, and patients often wonder which one works faster. The clinical data suggests they’re comparable in onset. In Ingrezza’s pivotal trial (KINECT-3), both tested doses also showed significant improvement in involuntary movement scores by week two. Neither drug has a clear speed advantage over the other based on available head-to-head reviews.
The practical differences between the two are more about dosing and side effect profiles than how quickly they kick in. Ingrezza is taken once daily and has a simpler titration, while Austedo requires twice-daily dosing (or once daily with the extended-release formulation, Austedo XR) and a more gradual ramp-up. Both reach their full effect over a similar multi-week timeline.
What to Watch for During Titration
The dose-adjustment phase is when side effects are most likely to surface or shift. Drowsiness is one of the more common early experiences, and it can be pronounced enough to affect driving or operating machinery. Some people develop restlessness, agitation, or symptoms resembling Parkinson’s disease, such as stiffness or slowed movement. These are typically signals that the dose is too high, and your doctor will either hold the current dose or step back down.
Mood changes deserve particular attention. Austedo carries a boxed warning about increased risk of depression and suicidal thoughts, especially in people with Huntington’s disease. These changes are more likely at the beginning of treatment or after a dose increase. If you or someone close to you notices shifts in mood, new feelings of hopelessness, or unusual behavior changes during the titration period, that information needs to reach your prescriber quickly.
Your individual metabolism also affects how the drug behaves. A liver enzyme called CYP2D6 is responsible for breaking down Austedo, and some people process it much more slowly than others due to genetic differences. If you’re a slow metabolizer, the maximum safe dose drops from 48 mg to 36 mg per day. Your doctor may order a genetic test before or during treatment to check this, which can influence both the titration speed and your eventual maintenance dose.
Setting Realistic Expectations
Austedo reduces involuntary movements but doesn’t eliminate them entirely for most people. Clinical trials measured improvement using a standardized scoring system for abnormal movements, and while the treatment groups consistently outperformed placebo, the changes were moderate. Many patients experience a meaningful reduction in the severity and frequency of their movements, enough to improve daily function and reduce self-consciousness, but a complete stop of all symptoms is uncommon.
If you’ve been on Austedo for eight to twelve weeks at an adequate dose and haven’t noticed any change, that’s a reasonable point to reassess with your doctor whether the medication is the right fit. Some people respond well at lower doses and notice improvement within a few weeks, while others need to reach the higher end of the dosing range before the benefit becomes clear. Keeping a simple log of your symptoms, even just a daily rating of how noticeable your movements are, can help both you and your doctor judge whether the medication is doing its job during those early weeks when changes may be subtle.